Legal department outsourcing for a pharmaceutical company on IP matters is a model of strategically engaging external patent litigators and attorneys to manage litigation risks, revoke blocking competitor patents, protect against unfair patent linkage, and handle cross-border conflicts, ensuring the seamless market launch of medicinal products without inflating internal headcount.
- An in-house legal department of a pharma company focuses on regulatory compliance and contracts, whereas aggressive pharmaceutical patent disputes require highly specialized litigation expertise.
- Challenging originators’ “evergreen” patents on crystalline forms, isomers, and dosages is the primary tool for opening the market to domestic generics and biosimilars.
- The proper application of the Bolar exception under national case law protects generic companies from infringement allegations until the base patent expires.
- Coordinating actions through a single litigation office allows for the effective engagement of foreign counsel in cross-border disputes and prevents registration bans via counter-security mechanisms.
The pharmaceutical sector is one of the most capital-intensive and legally aggressive industries in the world. For a generic or biosimilar manufacturer, every single day of delay in launching a product translates to hundreds of thousands of dollars in direct losses and lost profits. Conversely, for originator companies, maintaining a monopoly through secondary patents is a matter of protecting billion-dollar blockbusters’ development investments. In this confrontation, a pharmaceutical company’s traditional in-house legal department inevitably faces resource constraints: supporting regulatory procedures with the Ministry of Health, handling distribution contracts, and managing labor issues leave no time for multi-year patent litigation wars. Outsourcing the litigation IP function becomes not just a cost-optimization measure, but an essential element in safeguarding the continuity of the pharmaceutical business.
Litigation Defense of Biosimilar and Generic Manufacturers’ Rights
The development of the pharmaceutical market is inextricably linked to the confrontation between originators and generic manufacturers, where a single in-house lawyer’s mistake can cost millions of dollars. Bringing a generic drug or complex biosimilar to market is almost always accompanied by the risk of facing a lawsuit from the original molecule’s owner. Specialized outsourcing of the IP department allows companies to build a preventive “freedom to operate” (FTO) strategy long before filing the registration dossier, identify potential patent landmines, and strike a preemptive legal blow.
Challenging Originators’ Evergreen Patents in Court
The most common tactic used by Big Pharma to extend monopolies after the expiration of the base patent on an active pharmaceutical ingredient (API) is creating a web of secondary (“evergreen”) patents. This involves patenting polymorphic modifications, salts, esters, specific dosage regimens, combinations of known substances, or new therapeutic uses. Such patents often lack genuine inventive step, creating artificial barriers to bringing affordable generics to the market.
According to Article 33 of the Law of Ukraine “On Protection of Rights to Inventions and Utility Models,” a patent may be invalidated by a court if the patented invention fails to meet patentability conditions: novelty, inventive step, and industrial applicability. In judicial disputes regarding the invalidation of a patent for medicines, court expertise of pharmaceutical inventions—conducted by certified forensic experts from research institutes of forensic examinations under the Ministry of Justice—plays a decisive role. The primary task of an external patent litigator is to correctly formulate questions for the expert examination, proving that the proposed solution was obvious to a person skilled in the art and followed from the existing state of the art.
| Comparison Parameter | Base Patent on Molecule (API) | Secondary (“Evergreen”) Patent |
|---|---|---|
| Object of Legal Protection | A new chemical compound or biological molecule obtained for the first time. | Polymorphic form, optical isomer, dosage regimen, excipient composition. |
| Resistance Level to Challenges | High. Novelty and inventive step are usually indisputable. | Low to medium. Highly vulnerable under the “inventive step” criterion. |
| Litigation Challenge Methodology | Proving procedural violations during application filing or disclosure defects. | Searching for earlier publications (prior art), proving the obviousness of synthesizing the form. |
| Key Focus of Expertise | Identification of chemical structure and global state of the art as of the priority date. | Absence of unexpected therapeutic synergy or new technical result. |
To build a strong position in Ukrainian courts, external counsel thoroughly analyze the prosecution history of related patent applications in leading offices, utilizing, in particular, the registers and practice of the EUIPO (European Union Intellectual Property Office) and the European Patent Office (EPO). If European bodies refused to grant a patent due to a lack of inventive step, these materials, properly legalized, become compelling indirect evidence in commercial proceedings in Ukraine.
Application of the Bolar Exception and Infringement Risks
For generic companies, it is critical to register their drug and be ready to start sales on the very day the originator’s base patent expires. However, registration procedures and clinical trials take years. This is where the “Bolar exception” comes into play, enshrined in Ukrainian legislation by part three of Article 31 of the Law of Ukraine “On Protection of Rights to Inventions and Utility Models.” According to this norm, using a patented invention while preparing and submitting information for the registration of a medicinal product is not recognized as an infringement of rights.
When an open conflict with a patent holder arises, timely representation in court in the field of intellectual property makes it possible to promptly prove the lawfulness of the domestic manufacturer’s actions and fend off counterfeiting accusations as early as the preparatory proceedings stage.
Nevertheless, the domestic market is often just part of a broader geographic strategy requiring global control over disputes, since modern pharmaceutical companies’ manufacturing, packaging, and sales markets are distributed across various jurisdictions.
Managing Cross-Border Patent Disputes in Pharmaceuticals
Patent wars rarely stay confined to a single country, as launching a new blockbuster or biosimilar is planned simultaneously across dozens of markets. When a foreign original drug manufacturer files lawsuits for exclusive rights infringement simultaneously in Germany, Poland, and Ukraine, the local pharma company’s internal legal department collapses under the weight of differing jurisdictional procedures and language barriers. An external team acts as a single coordination hub, synchronizing litigators’ actions on all fronts.
Synchronizing Judicial Proceedings Across Multiple Jurisdictions
The main risk of a cross-border dispute is the so-called “positional conflict.” This occurs when local lawyers in one jurisdiction submit arguments or expert conclusions that completely contradict the defense line chosen in another country. Patent holders instantly exploit such contradictions to destroy the court’s trust in the generic company.
Key Action: Gathering statements of claim, objections, and court orders across all involved jurisdictions (Ukraine, EU, USA).
Goal / Requirement: Comparing the scope of claims in national patents issued for a single molecule under a convention application.
Result: A patent vulnerability map and identification of common grounds for challenge.
Key Action: Engaging leading chemists and pharmacologists to develop a unified scientific defense basis.
Requirement: Scientists’ statements must not contain mutually exclusive interpretations of the molecule structure or crystal stability.
Result: A standardized package of scientific and technical conclusions for submission to national courts and the UPC.
Action: Regular procedural briefings with foreign legal counsel and patent attorneys.
Requirement: Strict timing control over the submission of procedural documents to avoid res judicata traps.
Result: A mirrored offensive against the validity of the opponent’s patents simultaneously in several countries.
Body / Action: Filing counterclaims and applications for declaratory relief of non-infringement.
Basis: Provisions of procedural codes on preventing damages from production halts.
Result: Blocking the originator’s attempts to obtain pan-European injunctions on goods movement.
Protection Against Cross-Border Substance Export Blocking
Another threat to pharmaceutical enterprises is the blocking of active substance (API) imports or finished dosage form exports through customs authorities. Patent holders actively utilize the Customs Register of Intellectual Property Rights Objects. When a batch of raw materials arrives, customs clearance may be suspended at the right holder’s initiative based on suspected patent infringement.
For a pharmaceutical plant’s manufacturing cycle, raw material delays at customs mean broken validation schedules and million-dollar contract penalties. External patent litigators take comprehensive measures: from submitting reasoned objections to customs authorities regarding the application of the Bolar exception to obtaining commercial court decisions refusing interim relief or canceling customs suspensions.
For effective work in international jurisdictions, it is critical to be able to instantly engage and coordinate local counsel without losing project control.
Engaging Foreign Counsel in Patent Disputes
The success of a cross-border case directly depends on the smooth cooperation between Ukrainian litigation lawyers and foreign colleagues during evidence collection and expert examinations. If a dispute unfolds simultaneously in Ukraine and abroad, finding qualified litigation lawyers (foreign counsel) in specific European countries or the USA must happen within days.
Criteria for Selecting Foreign Legal Counsel
Choosing the wrong foreign counsel is exceptionally costly. The specifics of Pharma & Life Sciences mean that most top-tier law firms (Chambers, Legal 500) face a “conflict of interest” because they already service multinational Big Pharma corporations globally.
- Strict Conflict of Interest Compliance: Verifying the absence of direct or indirect representation of the opposing company in other practices of the foreign firm (M&A, regulatory, tax).
- Deep Technical Team Expertise: Availability of counsel team members with academic degrees in organic chemistry, molecular biology, or biopharmaceuticals.
- Practical Experience in Specific Court Instances: Proven track record of successfully defending generic companies against originators specifically in patent courts of the dispute jurisdiction (e.g., Federal Patent Court of Germany or the UPC).
- Pricing Flexibility and Readiness for Fixed Budgets: Ability of foreign colleagues to work under transparent capped hourly rates or milestone-based payments without hidden administrative markups.
- Readiness for Daily Operational Interaction: Having an assigned contact partner available 24/7 to synchronize positions with the Ukrainian team.
- Experience Providing Evidence for Foreign Courts: Understanding the specifics of drafting affidavits and expert opinions according to standards acceptable under Ukrainian procedural legislation.
Legalization of Foreign Evidence and Procedural Deadlines
Any evidence from abroad—even the most convincing conclusion from a foreign scientific institute regarding the absence of an inventive step, or a German court ruling invalidating a patent—has no legal force in a Ukrainian court without proper execution. The Commercial Procedural Code of Ukraine establishes strict admissibility requirements for evidence.
The external litigation team ensures the timely completion of the apostille procedure (pursuant to the 1961 Hague Convention) or consular legalization of documents obtained abroad, their notarized translation into Ukrainian, and their inclusion in the case materials within the preparatory proceedings deadlines. Violating these requirements leads to evidence rejection by the court under part two of Article 118 of the Commercial Procedural Code of Ukraine.
Properly gathered international evidence forms the foundation for overcoming attempts to block product launches via patent linkage mechanisms.
Patent Linkage and Countering Registration Blocking
The most destructive tactical move by originators remains blocking the state registration of generics through patent linkage institutes and interim relief measures. Patent linkage involves tying the regulatory registration of a medicinal product at the Ministry of Health of Ukraine to the patent status of the original drug. Patent holders use lawsuits against the Ministry of Health and the State Expert Center of the Ministry of Health of Ukraine as tools of unfair competition, trying to completely paralyze the generic registration procedure.
Case Law on Interim Relief for Pharmaceutical Companies
A typical scenario: upon learning of a generic company’s intention to register a drug, the patent holder applies to a commercial court with an intellectual property infringement lawsuit and simultaneously files an application for interim relief. In the application, the plaintiff demands: prohibiting the Ministry of Health from adopting decisions on state registration of the medicinal product, prohibiting entering information into the State Register of Medicinal Products of Ukraine, or suspending the effect of an already issued registration order.
According to Article 137 of the Commercial Procedural Code of Ukraine, interim relief measures must be proportional to the stated claims. The Grand Chamber of the Supreme Court has repeatedly pointed out that court relief must not replace the resolution of the dispute on the merits and effectively establish the plaintiff’s monopoly on the market before the actual fact of a violation is proven. Timely IP legal protection enables the generic company to prevent such rulings or overturn them in the appellate court.
Strategies for Lifting Restrictive Measures in Court
The key tool for neutralizing unfair Big Pharma lawsuits is the counter-security institute. If the first-instance judge nevertheless granted the interim relief application without summoning the parties, the generic’s defense files an application detailing the plant’s monthly losses: production line downtime, raw material spoilage, storage costs for drug batches in licensed warehouses, and distributor penalties.
When counter-security amounts reach 10–50 million hryvnias, the originator plaintiff faces a dilemma: either freeze a huge amount of liquid funds on a Ukrainian court deposit without a guarantee of winning the case, or abandon the blocking attempt. Usually, if counter-security is not deposited within the set deadline, the court, upon the generic litigators’ motion, completely cancels the applied interim relief measures.
Concurrently with judicial defense, an appeal is submitted to the Antimonopoly Committee of Ukraine (AMCU) regarding the right holder’s actions exhibiting signs of unfair competition and abuse of monopoly power, creating significant financial and reputation risks for the aggressive patent holder.
To effectively repel such procedural attacks 24/7, pharma companies need a systematic outsourcing model for their litigation function.
Effective Outsourcing Model for the Litigation IP Department
All the challenges described prove that maintaining a full in-house staff of highly specialized patent litigators within a pharma company structure is economically and organizationally unjustifiable. Most of the time, such a high-caliber in-house IP litigator would be underutilized, yet during dispute escalations, a single person is physically incapable of running parallel proceedings in courts, the Appeals Chamber of the IP Office, and controlling foreign jurisdictions. The optimal solution is a hybrid model combining the in-house team and external consultants.
Division of Functions Between In-House Lawyers and Litigators
A clear division of responsibilities prevents duplicated actions and guarantees flawless quality in preparing procedural documents. The pharma company’s internal lawyers act as knowledge carriers regarding the product, internal production processes, and regulatory relations with state bodies. The external IP department takes over litigation strategy, court representation, and IP rights defense against unfair encroachments.
To divide responsibilities and establish operational interaction, the RACI management matrix (Responsible, Accountable, Consulted, Informed) works best:
- Patent market monitoring and threat identification (FTO analysis): In-house legal department (C), External IP Office / Patent Attorneys (R / A), R&D department (C).
- Support for routine registration actions at the Ministry of Health: In-house regulatory department (R / A), External IP Office (I).
- Developing patent invalidation strategy: In-house legal department (C), External IP Office / Litigation Lawyers (R / A), Pharma top management (I).
- Litigation process and questioning of forensic experts in the Supreme Court: External IP litigators (R / A), In-house lawyers (C / I).
- Engaging and auditing foreign counsel: External IP Office (R / A), Head of in-house department (C / I).
- Responding to criminal proceedings and customs seizures: External IP lawyers (R / A), In-house lawyers (C).
Budget Control and Mitigation of Procedural Risks
Outsourcing ensures complete transparency of company expenses. Instead of fixed costs for salaries, taxes, training, and workstations for niche specialists, the pharmaceutical company pays for the external litigation office’s services through clear, flexible models: a fixed retainer fee for ongoing monitoring and preventive defense, plus hourly rates or milestone fees directly during litigation proceedings.
A significant advantage is the ability to fully recover legal assistance costs from the opponent upon winning a lawsuit. According to the established practice of the Cassation Commercial Court within the Supreme Court, costs for lawyers engaged under legal assistance agreements (outsourcing) are subject to compensation at the expense of the losing party, provided they are realistic and proportional to the case’s complexity. Conversely, maintaining in-house lawyers is part of general business operating expenses and is not compensated by opponents based on court outcomes.
Synergy Between Litigation Representation and Pharma In-House Teams
A pharmaceutical patent dispute is a large-scale business battle for control over medicinal product market shares. Victory goes not to the number of lawyers on the payroll, but to the depth of technical-legal specialization, procedural response speed, and litigator strategic thinking. Continuous pressure from “evergreen” patents, registration blocking threats via patent linkage, and cross-border coordination needs make outsourcing the litigation IP department an indispensable choice for progressive pharma companies.
The tandem of in-house lawyers—who flawlessly understand internal regulatory operations—and external litigation lawyers hardened in patent battles at the Supreme Court and international instances builds an insurmountable defense line. It is time to audit your product portfolio risks and entrust IP litigation defense to an experienced team of litigators to guarantee production stability and investment security.
